Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment
The American Journal of Managed Care · 2026
DOI: 10.37765/ajmc.2026.90025 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Managed Care, 2026. Verfasst von Michael R Eber und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Deductibles and Coinsurance, Antineoplastic Agents, Health Benefit Plans, Employee, Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Population Medicine, Harvard Medical School, Boston, MA.
- Harvard Pilgrim Health Care Institute, Boston, MA.
- Department of Resource Economics, University of Massachusetts Amherst, Stockbridge Hall, 80 Campus Center Way, Amherst, MA 01003. Email: meber@umass.edu.
- Harvard Center for Health Decision Sciences, Boston, MA.
- Department of Medicine, Duke University, Durham, NC.
- Duke-Margolis Institute for Health Policy, Durham, NC.
Zitieren
APA
Eber, M. R., Costa, R., Argetsinger, S., Shahzad, M., Zhang, F., Wharam, J. F., Ross-Degnan, D., & Wagner, A. K. (2026). Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment. The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2026.90025
Vancouver
Eber MR, Costa R, Argetsinger S, Shahzad M, Zhang F, Wharam JF, et al. Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment. The American Journal of Managed Care. 2026. doi:10.37765/ajmc.2026.90025
BibTeX
@article{Eber2026,
author = {Eber, Michael R and Costa, Rebecca and Argetsinger, Stephanie and Shahzad, Mahnum and Zhang, Fang and Wharam, J Frank and Ross-Degnan, Dennis and Wagner, Anita K},
title = {Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment},
journal = {The American Journal of Managed Care},
year = {2026},
doi = {10.37765/ajmc.2026.90025}
}
EUVIMED